Monday, June 24, 2024


Dhaka Tribune

Covid-19: BSMMU study finds antibodies in 98% of AstraZeneca vaccine recipients

No complex side effects, including blood clotting, were observed during the BSMMU study

Update : 02 Aug 2021, 01:07 PM

A Bangabandhu Sheikh Mujib Medical University (BSMMU) study has found antibodies in 98% of people who have received the AstraZeneca Covid-19 vaccine.

The study, released on Monday, said that those who had Covid-19 before and were vaccinated after recovering were found to have high levels of antibodies.

BSMMU Vice-Chancellor (VC) Prof Dr Sharfuddin Ahmed had led the research, titled "Haematological Parameters and Antibody Titre After Vaccination Against Sars-CoV-2.” 

Also Read - Covid: Bangladesh records 231 more deaths, 14,844 new cases

Some 209 recipients of the Covid-19 vaccine had volunteered for the study conducted between April and July this year, reports The Business Standard.

Three-quarters of the participants were male and more than half were from the healthcare sector.

Of the participants, 31% have had Covid-19, while more than half were already suffering from diabetes, high blood pressure, asthma, and other diseases.

However, The Business Standard, citing the study, reported that no difference was observed in the production of antibodies after vaccination in those suffering from these diseases.

Also Read - 'Covid shot protection highly likely to wane over time'

A total of 42% of participants had reported side effects after vaccination, with mild symptoms in all cases. But blood clotting or any other such complex side effects were not observed during the study.

The study also found that there is no correlation between the presence of antibodies and adverse effects and those who had previously contracted the virus had more antibodies than others.

BSMMU's Pro-VC (Research and Development) Prof Dr Md Zahid Hossain, Pro-VC (Education) Prof Dr AKM Mesharroff Hossain, and Hematology Department Chairman Prof Dr Md Salahuddin Shah were the co-researchers in the study.

Also Read - DGHS: Administration of second dose of AstraZeneca jabs to resume from Monday

According to DGHS, as of Sunday morning, around 4.298 million people received the second dose of the Oxford-AstraZeneca Covid-19 vaccine.

Meanwhile, about 1.52 million have been administered the first dose and are awaiting the second one.

Top Brokers


Popular Links